Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

Inclusion Criteria: * Patients must have histologically confirmed malignancy that is metastatic or unresectable * Cancers with positive BRAF V600 mutation detected by a Clinical Laboratory Improvement Act (CLIA)-certified laboratory * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * Life expectancy of greater than 3 months * Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria * Patients must have a K-RAS wild-type (WT) tumor * Absolute neutrophils count \>= 1500/mcl (within 14 days) * Platelets \>= 100000/mcl (within 14 days) * Hemoglobin (Hb) \>= 9 mg/dl (within 14 days) * Total bilirubin =\< 1.5 mg/dl (within 14 days) * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 5 x upper limit of normal if liver metastases present; otherwise, then =\< 2.5 x upper limit (within 14 days) * Estimated creatinine clearance by Cockcroft-Gault equation \> 30 mL/min (within 14 days) * Current treatment may cause harm to the developing human fetus; for this reason women of child-bearing age must have a negative pregnancy test at screening and both women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, and for 6 months after last dose; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this stud…